RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - October 29, 2008) - Adherex Technologies Inc. (TSX: AHX) (AMEX: ADH), a biopharmaceutical company dedicated to solving problems for patients with cancer, today announced that Dr. William P. Peters, Adherex's Chairman and CEO, will be presenting at Windhover Information's Therapeutic Area Partnerships Meeting on Tuesday, November 4, 2008 at the Loews Philadelphia Hotel. Adherex's sodium thiosulfate (STS), a chemoprotectant being developed to reduce or prevent the hearing loss often associated with platinum-based chemotherapies, was selected by Windhover as one of the Top 10 most interesting oncology projects available for partnering. The independent selection committee was led by Marc Wortman, PhD, contributing writer to Windhover's In Vivo and Start Up magazines, and a team from the pharmaceutical and biotech management consulting firm, Campbell Alliance. This is the second time an Adherex product has been selected, with ADH-1 being honored as a Top 10 project by Windhover last year.
